PMV Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMVP research report →
Range $5 – $5
Price Chart
About the company
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state.
- CEO
- David H. Mack
- IPO
- 2020
- Employees
- 54
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on PMVP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.72M
- P/E
- -0.85
- Fwd P/E
- 3.89
- PEG
- -0.35
- P/S
- 0.00
- P/B
- 1.52
- EV/EBITDA
- -0.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -110.22%
- ROIC
- -76.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-86,206,000
- Net Income
- $-77,742,000-32.4%
- EPS
- $-1.48-30.0%
- OCF Growth
- -43.5%
- FCF Growth
- -41.7%
- 52W High
- $1.91
- 52W Low
- $0.66
- 50D MA
- $1.37
- 200D MA
- $1.31
- Beta
- 1.35
- RSI (14)
- 31
- Avg Volume
- 787.50K
No earnings-call transcripts are available for PMVP yet.
- Free Float
- 91.7%
- Shares Outstanding
- 53.33M
- Float Shares
- 48.90M
of shares held by institutions
65 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bml Capital Management, LLC | 7.33M | ▲ 2.00M |
| Tang Capital Management LLC | 4.25M | 0 |
| Vanguard Capital Management LLC | 3.08M | ▲ 1.07M |
| Sio Capital Management, LLC | 2.63M | ▼ 442.44K |
| Euclidean Capital LLC | 2.63M | 0 |
| Adage Capital Partners Gp, L.L.C. | 2.36M | ▲ 500.00K |
| Acadian Asset Management LLC | 2.29M | ▲ 69.58K |
| Vanguard Group Inc | 2.17M | ▲ 7.28K |
| Arrowmark Colorado Holdings LLC | 1.96M | ▼ 913.18K |
| Two Sigma Investments, LP | 1.95M | ▲ 69.61K |
| Eversept Partners, LP | 1.89M | ▼ 457.46K |
| Affinity Asset Advisors, LLC | 1.75M | ▲ 1.75M |
Held by 28 ETFs
Biggest fund positions in PMVP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Eckler Matthew Joseph | other | 84,000 |
| Oct 1, 26 | Eckler Matthew Joseph | other | 0 |
| Jun 4, 26 | Stelzer Laurie | other | 42,000 |
| Jun 4, 26 | LEVINE ARNOLD J | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | FLOWERS KIRSTEN | other | 42,000 |
| Jun 4, 26 | BAUM CHARLES M | other | 42,000 |
| Mar 5, 26 | Carulli Michael | other | 240,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PMVP coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PMVP?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
globenewswire.com · Nov 20
Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
globenewswire.com · Nov 4
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
zacks.com · Oct 12
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
seekingalpha.com · Oct 7
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts
defenseworld.net · Sep 29
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
zacks.com · Sep 16
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
globenewswire.com · Aug 31
PMV Pharma Announces Proposed Public Offering of Securities
globenewswire.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
